Campbell Stephanie, Sun Can-Lan, Kurian Seira, Francisco Liton, Carter Andrea, Kulkarni Sameer, Parker Pablo, Karanes Chatchada, Forman Stephen J, Bhatia Smita
Department of Population Sciences, City of Hope National Medical Center, Duarte, California 91010-3000, USA.
Cancer. 2009 Sep 15;115(18):4127-35. doi: 10.1002/cncr.24474.
Avascular necrosis (AVN) is a debilitating condition reported after chronic steroid use. The purpose of this study was to describe the magnitude of risk in individuals who survived >or=1 years after hematopoietic cell transplantation (HCT), and to investigate the role of immunosuppressive agents such as prednisone, tacrolimus (FK506), mycophenolate mofetil (MMF), and cyclosporine (CSA) in the development of AVN after HCT.
Using a retrospective study design, the authors followed 1346 eligible patients for the development of AVN. Cumulative incidence was calculated taking into consideration competing risk from death and disease recurrence. Cox proportional regression techniques were used to identify associated risk factors.
The median age at HCT was 34 years (range, 7 months-69 years), and median length of follow-up for those surviving was 8.2 years. Seventy-five patients developed AVN of 160 joints. The cumulative incidence of AVN at 10 years was 2.9% after autologous HCT, 5.4% after allogeneic matched related donor HCT, and 15% after unrelated donor HCT (P<.001 compared with autologous HCT recipients). For allogeneic transplant recipients, male sex (relative risk [RR], 2.1; 95% confidence interval [95% CI], 1.1-4.0); presence of chronic graft-versus-host disease (RR, 2.2); and exposure to CSA, FK506, prednisone, and MMF rendered patients at increased risk, especially in patients with a history of exposure to >or=3 drugs (RR, 9.2; 95% CI, 2.42-35.24).
Future studies examining the pathogenetic mechanism underlying AVN should help develop targeted interventions to prevent this chronic debilitating condition.
无血管性坏死(AVN)是慢性使用类固醇后报告的一种使人衰弱的病症。本研究的目的是描述造血细胞移植(HCT)后存活≥1年的个体的风险程度,并调查免疫抑制剂如泼尼松、他克莫司(FK506)、霉酚酸酯(MMF)和环孢素(CSA)在HCT后AVN发生中的作用。
采用回顾性研究设计,作者随访了1346例符合条件的患者是否发生AVN。计算累积发病率时考虑了死亡和疾病复发的竞争风险。使用Cox比例回归技术识别相关风险因素。
HCT时的中位年龄为34岁(范围7个月至69岁),存活者的中位随访时间为8.2年。75例患者出现160个关节的AVN。自体HCT后10年AVN的累积发病率为2.9%,同种异体匹配相关供体HCT后为5.4%,无关供体HCT后为15%(与自体HCT受者相比,P<0.001)。对于同种异体移植受者,男性(相对风险[RR],2.1;95%置信区间[95%CI],1.1 - 4.0);存在慢性移植物抗宿主病(RR,2.2);以及接触CSA、FK506、泼尼松和MMF使患者风险增加,尤其是有接触≥3种药物史的患者(RR,9.2;95%CI,2.42 - 35.24)。
未来研究AVN潜在发病机制的研究应有助于开发针对性干预措施以预防这种慢性衰弱病症。